Table 3.
Synergism analysis of various schedules of administration of bortezomib { 131 I-MIBG + topotecan}
| Effect level |
Combination index* |
Combination index* |
||||
|---|---|---|---|---|---|---|
|
SK-N-BE(2c) cells |
UVW/NAT cells |
|||||
| Simultaneous | BZ before | BZ after | Simultaneous | BZ before | BZ after | |
| ED25 |
1.46 |
1.42 |
0.64 |
1.30 |
1.71 |
0.77 |
| ED50 |
1.54 |
1.70 |
0.63 |
1.44 |
2.02 |
0.77 |
| ED75 | 1.63 | 2.04 | 0.63 | 1.60 | 2.41 | 0.79 |
Asterisk '*’ indicates that the combination index values are means of four experiments. Administration schedules were simultaneous, bortezomib 24 h before {131I-MIBG + topotecan} (BZ before) and bortezomib 24 h after {131I-MIBG + topotecan} (BZ after). Italicised values indicate synergy.